Table 1. The prevalence of haemorrhagic stroke among COVID-19 patients around the globe.
| Study Design | Country | NOS | COVID-19 | Chronology of the symptoms | Ref | ||||
|---|---|---|---|---|---|---|---|---|---|
| Haemorrhagic
Stroke |
Total
COVID-19 |
Not
clear (%) |
Respiratory
symptoms first (%) |
Neurologic
symptoms first (%) |
|||||
| Case | Death | ||||||||
| Retrospective cohort | US | 8 | 35 | 16 | 5227 | 35 (16.2) | - | - | 32 |
| Retrospective cohort | US | 8 | 33 | 14 | 3824 | - | 29 (13.4) | 4 (1.85) | 33 |
| Prospective cross-
sectional |
Spain | 7 | 1 | - | 2000 | - | 1 (0.46) | - | 34 |
| Retrospective cohort | Spain | 8 | 5 | 2 | 1683 | - | 4 (1.85) | 1 (0.46) | 35 |
| Retrospective cohort | US | 8 | 9 | 5 | 3218 | - | 5 (2.31) | 4 (1.85) | 36 |
| Retrospective cohort | UEA | 8 | 12 | 4 | 591 | 12 (5.55) | - | - | 37 |
| Retrospective cohort | Turkey | 7 | 2 | - | 239 | 2 (0.93) | - | - | 38 |
| Retrospective cohort | US | 8 | 14 | - | 10,596 | 14 (6.48) | - | - | 39 |
| Retrospective cohort | China | 8 | 1 | 1 | 219 | - | 1 (0.46) | - | 40 |
| Retrospective cohort | US | 8 | 1 | - | 509 | 1 (0.46) | - | - | 41 |
| Retrospective cohort | Italy | 7 | 2 | - | 213 | 2 (0.93) | - | - | 42 |
| Retrospective cohort | US | 8 | 8 | - | 650 | - | 2 (0.93) | 6 (2.78) | 43 |
| Retrospective cohort | Italy | 8 | 11 | - | 1760 | 11 (5.09) | - | - | 44 |
| Retrospective cohort | UK | 8 | 14 | 4 | 3403 | 14 (6.48) | - | - | 45 |
| Retrospective cohort | Multi-
national |
8 | 27 | - | 17,799 | 27 (12.5) | - | - | 46 |
| Retrospective cohort | US | 7 | 3 | - | 90 | - | 3 (1.39) | - | 47 |
| Retrospective cohort | Multi-
national |
8 | 28 | 16 | 14,483 | 28
(12.96) |
- | - | 48 |
| Retrospective cohort | China | 7 | 10 | 4 | 651 | 10 (4.63) | - | - | 49 |
| Total | 216 | 66 | 67,155 | 156/216
(72.2) |
45/216
(20.83) |
15/216
(6.94) |
|||
NOS = Newcastle-Ottawa scale score, COVID-19 = coronavirus disease 19